Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CTLA4 methylation predicts response to anti–PD-1 and anti–CTLA-4 immunotherapy in melanoma patients

11 Jul 2018

Abstract excerpt

Recent years have witnessed the groundbreaking success of immune checkpoint blockage (ICB) in metastasized malignant melanoma. However, biomarkers predicting the response to ICB are still urgently needed. In the present study, we investigated CTLA4 promoter methylation (mCTLA4) in 470 malignant melanoma patients from The Cancer Genome Atlas (non-ICB cohort) and in 50 individuals with metastasized malignant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Immune cells in cancer
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29997292
DOI: 10.1172/jci.insight.96793

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CTLA4 methylation predicts response to anti–PD-1 and anti–CTLA-4 immunotherapy in melanoma patientsPMID 29997292Read ↗

CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)Semantic proximity Read ↗

Integrated multi-omics profiling reveals the role of the DNA methylation landscape in shaping biological heterogeneity and clinical behaviour of metastatic melanomaSemantic proximity Read ↗

A four-DNA methylation biomarker is a superior predictor of survival of patients with cutaneous melanomaSemantic proximity Read ↗

Integrated multi-omics profiling reveals the role of the DNA methylation landscape in shaping biological heterogeneity and clinical behaviour of metastatic melanomaSemantic proximity Read ↗

DNA Methylation Signatures Correlate with Response to Immune Checkpoint Inhibitors in Metastatic MelanomaSemantic proximity Read ↗

Pre-treatment DNA methylome and transcriptome profiles correlate with melanoma response to anti-PD1 immunotherapySemantic proximity Read ↗

Analysis of DNA methylation patterns in the tumor immune microenvironment of metastatic melanomaSemantic proximity Read ↗

DNA methylation regulates TIGIT expression within the melanoma microenvironment, is prognostic for overall survival, and predicts progression-free survival in patients treated with anti-PD-1 immunotherapySemantic proximity Read ↗

Genomic and Epigenomic Biomarkers of Immune Checkpoint Immunotherapy Response in Melanoma: Current and Future PerspectivesSemantic proximity Read ↗

Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance.Semantic proximity Read ↗

DNA methylation variations of DNA damage response correlate survival and local immune status in melanomas.Semantic proximity Read ↗

Epigenetic modifiers to enhance the efficacy of immune checkpoint inhibitors for the treatment of melanomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.